drugset
drugset / Trial / NCT02904226

JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors

NCT02904226 ↗

Phase 1/2 Completed 242 enrolled Jounce Therapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone and in combination with nivolumab, ipilimumab, or pembrolizumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

Timeline

Start
2016-08
Primary completion
2020-07-01
Completion
2020-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody — Intravenous
Subject Nivolumab Monoclonal antibody — Intravenous
Subject Pembrolizumab Monoclonal antibody — Intravenous
Subject Vopratelimab Monoclonal antibody — Intravenous

Indications

cancer